Study of Nilotinib usefulness for chronic myeloid leukemia (CML) patients with Imatinib resistant or intolerant.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Apr 2012
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacogenomic; Therapeutic Use
- 14 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 09 Feb 2010 New trial record